• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Point-of-care molecular testing for COVID-19 may offer fast, reliable results

byMichael PratteandRavi Shah, MD MBA
October 21, 2020
in Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Use of the novel molecular point-of-care testing, the QIAstat-Dx Respiratory SARS-CoV-2 Panel, was associated with a much shorter time to results compared to laboratory PCR testing.

2. Point-of-care testing demonstrated superior specificity and sensitivity to standard PHE RdRP and E gene assay for COVID-19.

Evidence Rating Level: 2 (Good)

Study Rundown: As the SARS-CoV-2 pandemic continues to ravage healthcare systems throughout the world, the need for rapid, effective testing for the virus has become more important than ever. Although several tests for the virus now exist, a major bottleneck is the long wait time to receive results. This, in turn, leads to patients being isolated too late, going through multiple bed transfers and exposing numerous others in the hospital to the virus. This prospective, interventional trial compared standard laboratory testing for COVID-19, PHE RdRp and E Gene assay testing, with a novel “point-of-care” screen, the QIAstat-Dx Respiratory SARS-CoV-2 Panel. Overall, the QIAstat-Dx screen significantly reduced the median time from presentation to receiving a designated COVID bed in hospital by as much as 20 hours; likewise, point-of-care testing was associated with fewer bed changes on average, and a higher overall sensitivity and specificity than either PHE RdRp and E Gene assays. Although this study provides strong support of this novel point-of-care testing method, there are some shortcomings. A major limitation of this study was that it was not randomized, due to this being deemed unethical in light of the global pandemic and may have resulted in patients with a higher likelihood of COVID being chosen for rapid, point-of-care testing. Similarly, given the poor sensitivity of the RdRp assay, it is possible that the QIAstat-Dx test may have had false negatives that the laboratory PCR test did not detect. This study also was only conducted on symptomatic patients, and thus its use as a screening tool in minimally-symptomatic or asymptomatic patients is unknown.

Click to read the study in The Lancet Respiratory Medicine

Click to read an accompanying editorial in The Lancet Respiratory Medicine

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

Relevant Reading: Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection.

In-Depth [prospective cohort]: This single-center, prospective, non-randomized interventional study was conducted between March 20 and April 29, 2020, and recruited 500 patients for the point-of-care COVID testing group, and 555 patients for the laboratory PCR group. Median age was 68 years in the former group, and 70 years in the latter, with roughly half being female and the majority being of White British ethnicity in both groups. The point-of-care group had a higher median NEWS2 score (an indicator of disease severity) than the control group (5 [IQR=3-6] vs. 4 [IQR=2-6]). Overall, the median time from presentation to hospital to arrival in a designated COVID ward was significantly lower in the point-of-care group than the laboratory PCR group (8.0h [IQR=6.0-15.0] vs. 28.8h [IQR=23.5-38.9], respectively; difference = 20.8h [IQR=18.4-21.2], p<0.0001). Patients in the point-of-care group also underwent fewer bed transfers on average (0.9 moves (SD=0.5) vs. 1.4 (SD=0.7), difference = 0.5 [95% CI = 0.4-0.6], p<0.0001). The QIAstat-Dx point-of-care test showed strong diagnostic test accuracy (sensitivity = 99.4% [95% CI = 96.9-100] & specificity = 98.6% [95% CI = 96.5-99.6]) compared to the PHE RdRp and E gene assays (sensitivity = 89.5% (95% CI = 83.6-93.9)).

Image: PD                         

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronaviruspoint-of-care testingQIAstat-DxSARS-CoV-2
Previous Post

#VisualAbstract: Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer

Next Post

Postpartum plasma metabolomic profile among women with preeclampsia and preterm delivery: implications for long-term health

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19
StudyGraphics

#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19

August 12, 2024
Next Post
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Postpartum plasma metabolomic profile among women with preeclampsia and preterm delivery: implications for long-term health

#VisualAbstract: Low dose edoxaban prevents stroke in elderly patients with atrial fibrillation

#VisualAbstract: Low dose edoxaban prevents stroke in elderly patients with atrial fibrillation

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

Incidence, risk factors, and in-hospital mortality of post-operative AKI following aortic dissection repair

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.